Open-source large language model-based on-premises pipeline for automated data extraction from unstructured electronic health records: a pilot study - Report - MDSpire
Advertisement
On-Premises Pipeline Utilizing Open-Source Large Language Models for Automated Extraction of Data from Unstructured Electronic Health Records: A Pilot Investigation
Clinical Report: On-Premises Pipeline Utilizing Open-Source LLMs for EHR Data Extraction
Overview
This pilot study evaluated an on-premises, open-source large language model (LLM)-based data extraction pipeline for automated extraction of data from unstructured electronic health records (EHRs). The results indicated high accuracy across various tasks.
Background
Data extraction from electronic health records (EHRs) is essential for clinical practice and research but is often labor-intensive and prone to errors. This study investigates the performance of LLMs in extracting structured data from unstructured medical texts.
Data Highlights
The study evaluated 14 mid-sized open-source LLMs across multiple tasks, achieving high accuracy rates in information extraction, binary classification, and multilevel classification.
Key Findings
Qwen3-30b-a3b-q8 achieved the highest overall accuracy of 0.954.
12 LLMs exhibited perfect accuracy (1.0) in information extraction tasks.
Llama3.2-vision-90b-q4 had the highest binary classification accuracy at 0.972.
Qwen3-30b-a3b-q8 also led in multilevel classification accuracy with a score of 0.940.
Nine LLMs demonstrated perfect response consistency, with others showing a Krippendorff’s alpha value of 0.999.
Clinical Implications
Further validation in larger studies is necessary to confirm these results.
Conclusion
This pilot study demonstrates the feasibility of LLM-based automated data extraction pipelines for EHRs.
As ASE convenes its 37th Scientific Sessions near Denver, the meeting will spotlight echocardiographic AI and big data, contrast-enhanced ultrasound, evolving guidelines, the Feigenbaum Lecture, and the future of the sonographer workforce.
According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.